Partner, Jenner & Block
Matthew S. Hellman is a litigator. He has been lead counsel in dozens of appellate matters, and has presented arguments in the U.S. Supreme Court, the U.S. Courts of Appeals, and in state appellate courts. In addition, he routinely presents arguments in the trial courts. Mr. Hellman’s cases involve a variety of issues such as commercial law, intellectual property and administrative law. He has argued important cases for corporations like Marriott, GE and General Dynamics.
In 2010, Law360 recognized Mr. Hellman as a “Rising Legal Star” in the practice of Appellate Law. In 2007, Jenner & Block recognized Mr. Hellman with the Albert E. Jenner, Jr. Pro Bono Award, which annually recognizes attorneys in the Firm with a strong commitment to pro bono or public service work. He has argued or supervised more than a dozen pro bono cases in the courts of appeals, including two capital cases.
Mr. Hellman is member of the firm’s Appellate and Supreme Court Practice. He is also a member of the Edward Coke Appellate Inn of Court, and an Associate Trustee for the Washington Lawyer’s Committee for Civil Rights and Urban Affairs. He serves as the Co-Chair of the DC Hiring and the Hiring Executive Committees and is also a member of the Associate Development and Evaluation Committee and the Finance Committee.
Partner, Supreme Court & Appellate Litigation Practice, Paul, Weiss, Rifkind, Wharton & Garrison LLP
Willy Jay is a partner at Paul, Weiss, Rifkind, Wharton & Garrison LLP, and head of the firm’s Supreme Court & Appellate Litigation Practice.
Prior to joining Paul, Weiss, Willy Jay was a partner in Goodwin’s Appellate and Supreme Court Litigation practice. After ten years leading that practice, he became co-chair of Goodwin’s broader Complex Litigation and Dispute Resolution practice. Willy used his deep experience litigating before the U.S. Supreme Court and U.S. Courts of Appeals, including more than 80 oral arguments, to help clients formulate winning appellate strategy. His appellate skill led Benchmark Litigation to name him the nationwide Appellate Lawyer of the Year for 2020. A former Assistant to the Solicitor General and Supreme Court clerk, he has argued 19 cases before the Supreme Court, briefed more than 60 Supreme Court cases on the merits, and briefed more than 150 cases at the certiorari stage. In recent years he argued five of the most significant intellectual-property cases at the Court, involving patent, copyright, and trademark law.
Willy has handled cases in every federal court of appeals as well. He has filed more than 300 briefs in federal and state appeals courts and argued in 11 federal circuits. He is a prominent advocate at the Federal Circuit, where he has argued 30 times, filed more than 120 briefs in patent appeals, and been recognized as “Appellate Litigator of the Year" by both Managing IP and LMG Life Sciences. Willy also regularly counsels clients on appellate strategy at the trial level, preparing and arguing key motions and post-trial briefing before district courts and federal and state administrative agencies.
Willy is recognized in Band 1 in two different appellate categories in Chambers USA: America’s Leading Lawyers for Business, where clients praise him for being "a rocket scientist" whose "spectacular brief writing" and "keen and analytical mind" enable him to “take any issue on appeal.” Another client noted that Willy "is an extraordinary litigator" who "has a unique way of synthesizing complex arguments and making them understandable." Other clients comment that Willy is “A super-efficient appellate litigator who is able to cut straight to the most critical issues and construct simple, persuasive arguments from extremely complex legal and factual records." Forbes named him to its inaugural list of America’s Top 200 Lawyers. Willy is also listed in Legal500 and Best Lawyers in America. Law360 named him an “Appellate MVP.” He has been named “Litigator of the Week” by the AmLaw Litigation Daily.
Willy has particular experience in appellate cases involving intellectual property (including patent, copyright, and trademark law), financial services, administrative law (with a particular focus on pharmaceutical regulation), environmental law, class action practice, federal preemption of state law, and the First Amendment (including campaign finance regulation, election law, and election crimes).
David L. Brennan Endowed Chair, Associate Professor, and Associate Director of the Center for Intellectual Property Law & Technology, The University of Akron School of Law
Emily Michiko Morris, an experienced teacher and scholar in specializing in patent law, particularly as it relates to biotechnology and university research, and is an expert on intellectual property and regulatory issues related to the pharmaceutical industry. Her research also focuses on comparative law and comparative intellectual property law. Professor Morris’ work has been published in books and leading journals, such as the Connecticut Law Review, the Stanford Technology Law Review, and the Harvard Journal of Gender and Law. Professor Morris is also currently a Scholar and Edison Fellow at the Center for Intellectual Property x Innovation Policy at George Mason University in Washington, D.C.
Professor Morris has been the recipient of numerous grants and awards, including a three-year, $250,000 fellowship as an Eastern Scholar at the Shanghai University of Political Science and Law, where she lived and worked for a year as a visiting professor. She has also taught as a visiting or guest professor at other universities in a number of other countries.
Before joining academia, Professor Morris earned her A.B., magna cum laude, from Harvard University and her J.D., magna cum laude, from the University of Michigan Law School, where she was an articles editor on the Michigan Law Review. Following graduation from law school, Professor Morris clerked for the Honorable Bruce M. Selya on the First Circuit Court of Appeals and practiced for three years as an associate in the Issue & Appeals group in the Washington D.C. office of Jones Day.
Partner, Duane Morris LLP
Brian Pandya is Partner at Duane Morris LLP. A member of the firm’s Trial Practice Group, Brian represents technology, manufacturing, and healthcare companies in high-stakes litigation, arbitrations, investigations and appeals. He has served as lead trial counsel in a range of intellectual property, antitrust, complex commercial and white-collar matters. He also regularly counsels clients on cybersecurity and national security issues, particularly matters concerning emerging technologies and artificial intelligence.
Before joining Duane Morris, Brian served at the U.S. Department of Justice as Deputy Associate Attorney General from 2019-21, where he oversaw investigations and litigation undertaken by the Antitrust Division and Civil Division and served on several high-profile task forces and trial teams. Brian was also previously a litigation and IP partner at another prominent Washington, DC firm.
Brian clerked for Judge Leonard Davis on the United States District Court for the Eastern District of Texas. He is a two-time recipient of the Federal Circuit Bar Association’s Pro Bono Advocacy Award for work on behalf of military veterans and has served as volunteer federal public defender in the Eastern District of Virginia, among many other bar and community engagements.
Brian graduated cum laude from the University of Michigan Law School, where he was articles editor of the Michigan Telecommunications and Technology Law Review, and with honors and high distinction in mechanical engineering from Penn State University, where he received the Ralph Dorn Hetzel Memorial Award.
Partner, Clement & Murphy PLLC
Matt’s practice focuses on solving complex legal issues wherever they arise. Matt has developed winning strategies and written successful motions and briefs in a wide array of complicated, high-profile cases at every level of the federal court system and in multiple state courts. At the Supreme Court, Matt has written dozens of successful cert-stage and merits briefs. At the court of appeals level, Matt has briefed and delivered oral argument on a wide range of constitutional and statutory issues. At the trial level, Matt has helped craft litigation strategy from the ground up, and has delivered closing argument in a week-long bench trial. Matt’s cutting-edge work has been recognized by the American Lawyer and Legal 500 U.S. Matt’s matters have addressed administrative law, antitrust, bankruptcy, federal jurisdiction, habeas corpus, intellectual property, labor and employment, products liability, res judicata, securities law, and statutory interpretation; the First, Second, Fifth, Sixth, Seventh, Eighth, Ninth, Tenth, Eleventh, Fourteenth, and Twenty-first Amendments; and multiple separation of powers and federalism issues. Matt maintains a robust pro bono practice, through which he has helped wrongly convicted criminal defendants secure their freedom.
Outside of Clement & Murphy, Matt teaches classes on constitutional law and the Supreme Court at Georgetown University. Matt is an avid, long-suffering fan of his hometown Angels and his adopted Arsenal Football Club. When he is not thinking about the law or watching sports, Matt enjoys spending time with his wife and golden retriever.
Associate Professor of Law, Center for Intellectual Property and Entrepreneurship, University of Missouri School of Law
Professor Lietzan researches, writes, and teaches primarily in the areas of food and drug regulation, intellectual property, and administrative law. Some of her recent scholarship has focused on the nature and purpose of the new drug approval system, federal regulation of fecal microbiota transplantation, federal regulation of products derived from cannabis, the political economy of the Hatch-Waxman (generic drug) statute, and incentives to study already approved drugs for new uses. She is an award-winning teacher, and she has been an elected member of the American Law Institute since 2006.
Professor Lietzan brings to her scholarship and teaching eighteen years of private practice experience, eight of them as a partner in the food and drug group at Covington & Burling in Washington, DC. In practice, she handled a wide range of complex legal problems and broader legislative and regulatory policy questions affecting FDA-regulated companies. This work included lifecycle management and strategy issues, regulatory strategy and advocacy, white collar defense, congressional investigations, briefing in products liability cases, and international regulatory policy work. She was involved in every major amendment to the Federal Food, Drug, and Cosmetic Act (FDCA) between 1997 and 2014 and was deeply immersed for more than a decade in the development of the Biologics Price Competition and Innovation Act of 2010. She has been consistently identified by her peers in private practice as a “Best Lawyer in America” in the categories of FDA law (since 2013) and Biotechnology Law (since 2007).
Professor Lietzan has held one leadership position or another at the Food and Drug Law Institute (FDLI) since 2004, including a stint on its Board of Directors from 2008 to 2012. She also held leadership positions in the American Bar Association’s Section of Science and Technology Law for fourteen years.
Professor Lietzan received a bachelor’s degree from the University of North Carolina, where she graduated with honors in history. She holds a master’s degree in history from UCLA and a law degree with high honors from Duke Law School.
Professor of Law, University of Baltimore School of Law (on leave); Senior Counsel, U.S. Department of Justice
Professor Dolin’s scholarship centers on patent law with a specific focus on how the patent regime affects innovation, especially in bio-pharmaceutical areas. His work in these areas includes a number of scholarly articles, presentations, amicus briefs, and congressional testimony.
Dr. Dolin is currently on leave from his academic duties while he serves as Senior Counsel in the Civil Rights Division of the United States Department of Justice.
From January 2020 to January 2022, Professor Dolin served as a resident Associate Justice of the Supreme Court of the Republic of Palau. In this role, he (together with other members of the Court) heard appeals in civil, criminal, administrative, and constitutional law matters.
Prior to joining the University of Baltimore School of Law, Professor Dolin held visiting appointments in other law schools. He also served as a law clerk to the Hon. Pauline Newman, of the U.S. Court of Appeals for the Federal Circuit and the late Hon. H. Emory Widener Jr., of the U.S. Court of Appeals for the Fourth Circuit.
Rumors that he has a real Russian bear in his office are entirely true.
Associate Professor of Law, Center for Intellectual Property and Entrepreneurship, University of Missouri School of Law
Professor Lietzan researches, writes, and teaches primarily in the areas of food and drug regulation, intellectual property, and administrative law. Some of her recent scholarship has focused on the nature and purpose of the new drug approval system, federal regulation of fecal microbiota transplantation, federal regulation of products derived from cannabis, the political economy of the Hatch-Waxman (generic drug) statute, and incentives to study already approved drugs for new uses. She is an award-winning teacher, and she has been an elected member of the American Law Institute since 2006.
Professor Lietzan brings to her scholarship and teaching eighteen years of private practice experience, eight of them as a partner in the food and drug group at Covington & Burling in Washington, DC. In practice, she handled a wide range of complex legal problems and broader legislative and regulatory policy questions affecting FDA-regulated companies. This work included lifecycle management and strategy issues, regulatory strategy and advocacy, white collar defense, congressional investigations, briefing in products liability cases, and international regulatory policy work. She was involved in every major amendment to the Federal Food, Drug, and Cosmetic Act (FDCA) between 1997 and 2014 and was deeply immersed for more than a decade in the development of the Biologics Price Competition and Innovation Act of 2010. She has been consistently identified by her peers in private practice as a “Best Lawyer in America” in the categories of FDA law (since 2013) and Biotechnology Law (since 2007).
Professor Lietzan has held one leadership position or another at the Food and Drug Law Institute (FDLI) since 2004, including a stint on its Board of Directors from 2008 to 2012. She also held leadership positions in the American Bar Association’s Section of Science and Technology Law for fourteen years.
Professor Lietzan received a bachelor’s degree from the University of North Carolina, where she graduated with honors in history. She holds a master’s degree in history from UCLA and a law degree with high honors from Duke Law School.
Andrew A. Hufford is an Intellectual Property attorney with Brinks Gilson & Lione. His practice emphasizes US and global patent prosecution in biopharma, chemistry, and plant genetics. He also has significant experience in patent and trade secret litigation, inter-partes review, and patent due diligence. Mr. Hufford is the Vice Chair of the Utah State Bar Intellectual Property Section; a founding member of the David K. Winder IP Inns of Court; and an active member of the American Bar Association’s IP Law Section.
Mr. Hufford was a Professor of Biology before practicing law. He holds a Bachelor of Science (Cum Laude, Phi Beta Kappa) and Master of Science in Biochemistry, and spent several years conducting clinical pharmacology research. He earned his J.D. from the University of Houston, where he was an Articles Editor with the Houston Journal of Health Law and Policy and a member of the Moot Court and Mock Trial teams.
Professor of Law, University of Baltimore School of Law (on leave); Senior Counsel, U.S. Department of Justice
Professor Dolin’s scholarship centers on patent law with a specific focus on how the patent regime affects innovation, especially in bio-pharmaceutical areas. His work in these areas includes a number of scholarly articles, presentations, amicus briefs, and congressional testimony.
Dr. Dolin is currently on leave from his academic duties while he serves as Senior Counsel in the Civil Rights Division of the United States Department of Justice.
From January 2020 to January 2022, Professor Dolin served as a resident Associate Justice of the Supreme Court of the Republic of Palau. In this role, he (together with other members of the Court) heard appeals in civil, criminal, administrative, and constitutional law matters.
Prior to joining the University of Baltimore School of Law, Professor Dolin held visiting appointments in other law schools. He also served as a law clerk to the Hon. Pauline Newman, of the U.S. Court of Appeals for the Federal Circuit and the late Hon. H. Emory Widener Jr., of the U.S. Court of Appeals for the Fourth Circuit.
Rumors that he has a real Russian bear in his office are entirely true.
Associate Professor of Law, Center for Intellectual Property and Entrepreneurship, University of Missouri School of Law
Professor Lietzan researches, writes, and teaches primarily in the areas of food and drug regulation, intellectual property, and administrative law. Some of her recent scholarship has focused on the nature and purpose of the new drug approval system, federal regulation of fecal microbiota transplantation, federal regulation of products derived from cannabis, the political economy of the Hatch-Waxman (generic drug) statute, and incentives to study already approved drugs for new uses. She is an award-winning teacher, and she has been an elected member of the American Law Institute since 2006.
Professor Lietzan brings to her scholarship and teaching eighteen years of private practice experience, eight of them as a partner in the food and drug group at Covington & Burling in Washington, DC. In practice, she handled a wide range of complex legal problems and broader legislative and regulatory policy questions affecting FDA-regulated companies. This work included lifecycle management and strategy issues, regulatory strategy and advocacy, white collar defense, congressional investigations, briefing in products liability cases, and international regulatory policy work. She was involved in every major amendment to the Federal Food, Drug, and Cosmetic Act (FDCA) between 1997 and 2014 and was deeply immersed for more than a decade in the development of the Biologics Price Competition and Innovation Act of 2010. She has been consistently identified by her peers in private practice as a “Best Lawyer in America” in the categories of FDA law (since 2013) and Biotechnology Law (since 2007).
Professor Lietzan has held one leadership position or another at the Food and Drug Law Institute (FDLI) since 2004, including a stint on its Board of Directors from 2008 to 2012. She also held leadership positions in the American Bar Association’s Section of Science and Technology Law for fourteen years.
Professor Lietzan received a bachelor’s degree from the University of North Carolina, where she graduated with honors in history. She holds a master’s degree in history from UCLA and a law degree with high honors from Duke Law School.
Andrew A. Hufford is an Intellectual Property attorney with Brinks Gilson & Lione. His practice emphasizes US and global patent prosecution in biopharma, chemistry, and plant genetics. He also has significant experience in patent and trade secret litigation, inter-partes review, and patent due diligence. Mr. Hufford is the Vice Chair of the Utah State Bar Intellectual Property Section; a founding member of the David K. Winder IP Inns of Court; and an active member of the American Bar Association’s IP Law Section.
Mr. Hufford was a Professor of Biology before practicing law. He holds a Bachelor of Science (Cum Laude, Phi Beta Kappa) and Master of Science in Biochemistry, and spent several years conducting clinical pharmacology research. He earned his J.D. from the University of Houston, where he was an Articles Editor with the Houston Journal of Health Law and Policy and a member of the Moot Court and Mock Trial teams.
Does Jarkesy Doom the Preserve Access to Affordable Generics and Biosimilars Act?
Matthew S. Hellman, William M. Jay, Emily Michiko Morris, Brian Pandya, Matthew D. Rowen
Reducing the cost of prescription drugs has been a bipartisan priority for years. One recent...
Topics
The Bayh-Dole Act and the Debate Over “Reasonable Price” March-In Rights
In 1980, Congress passed the bipartisan Patent and Trademark Law Amendments Act—better known as the...
Sandoz, Inc. v. Amgen, Inc. Post-Decision SCOTUScast
Erika Lietzan
On June 12, 2017, the Supreme Court decided Sandoz, Inc. v. Amgen, Inc. consolidated with...
Courthouse Steps: Sandoz Inc. v. Amgen Inc. - Podcast
Gregory Dolin, Erika Lietzan
In a decision likely to shape not only future biosimilar litigation but the biosimilar industry...
Courthouse Steps: Sandoz Inc. v. Amgen Inc.
TeleforumCourthouse Steps: Amgen, Inc. v. Sandoz, Inc. - Podcast
Andrew A. Hufford
The Biologics Price Competition and Innovation Act of 2010 (42 U.S.C. § 262) created an...
Courthouse Steps: Amgen, Inc. v. Sandoz, Inc.
Teleforum